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Abstract 
Self-inspection is a requirement of most Quality Management Systems. Within an 
organisation, it is a key process for self-assessing compliance to regulatory requirements. 
Done well, it can be a very informative system – highlighting gaps and driving improvement. 
However, these audits can vary in effectiveness and the contribution of the programme can 
be difficult to assess and measure. Ensuring that there is an effective system in place is 
challenging.  
This paper assesses how the effectiveness of self-inspection programmes is currently 
measured and reviews the expectations of quality system regulations and standards. Based 
on this research, a Self-Inspection Programme Effectiveness Assessment (SI-PEA) tool was 
developed. SI-PEA is a risk-based method for assessing effectiveness of the self-inspection 
programme, verifying compliance to current quality system regulations, and identifying if 
there are opportunities to improve the programme. The tool ultimately assigns a risk score to 
the programme’s overall effectiveness. The tool was developed for application in a 
pharmaceutical quality system but is suitable for application within any quality management 
system.  The developed SI-PEA tool has been successfully piloted across two companies to 




In the European Union (EU), self-inspection is a requirement of a pharmaceutical quality 
system and is used to monitor the application of Good Manufacturing Practice (GMP) [1] 
through the Quality Management System (QMS). Specifically, the requirement is that ‘There 
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is a process for self-inspection and/or quality audit1, which regularly appraises the 
effectiveness and applicability of the Pharmaceutical Quality System’  
The objective of self-inspection is to monitor the company’s compliance with GMP 
requirements, identify gaps, and implement change as required. The self-inspection 
programme is also a mechanism to highlight areas of continuous improvement within the 
QMS. The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) in their Q10 Guidance: Pharmaceutical Quality System 
[2] recommends using self-inspection as one performance indicator of the effectiveness of a quality system and 
as a means of identifying innovations that might enhance the quality system. The challenge is to understand 
how well the programme achieves these objectives.  
This research created a method or tool to measure the effectiveness of a self-inspection 
programme using a risk-based approach. This tool both assesses the performance of the self-
inspection programme and identifies opportunities for improvement, aligning with the intent 
of ICH Q10. A risk score is assigned based on the assessment criteria and this score is then 
used to track improvements to the programme, thereby demonstrating improvement. 
There were four stages and methods utilised in this research: 
1. A Literature Review was performed to summarise the expectations of a self-inspection 
programme across several quality system standards. This was supplemented with a review 
of publications specifically discussing the effectiveness of self-inspection 
 
2. A survey was conducted with quality specialists within the pharmaceutical industry to 




3. An interview was conducted with a representative of a regulatory authority – and 
published expert on this topic -to understand expectations 
 
4. The tool was developed and piloted across two companies. The output was analysed and 
determined to be informative and useful. 
 
1 Throughout the documents reviewed for this paper, the term self-inspection is interchangeable with the term 
internal audit. The meaning of both terms is the same and therefore no differentiation will be made throughout 
this paper.  
2







Self-Inspection is a requirement of many quality system standards and regulations. The 
standards selected for this review apply to the pharmaceutical industry or related sectors, 
such as the medical device sector. These references were used to develop a matrix of 
requirements (TABLE 1). The intent in analysing these requirements was to assure that all the 
requirements were captured in any subsequent assessment process. 
It was noted that, while there is a requirement to perform internal audits in the US Food and 
Drug Administration (FDA) quality system requirements for medical devices 21 CFR 820 [3], 
there is no requirement in the US pharmaceutical regulation 21 CFR 210/211 [4]. However, 
FDA have contributed to and endorsed ICH Q10 which, as discussed previously, recommends 
self-inspection as a key element in QMS performance review. Therefore both 21 CFR 820 and 
ICH Q10 were reviewed in detail for self-inspection requirements 
In addition, FDA are a member of the Pharmaceutical Inspection Co-Operation Scheme 
(PIC/S). The PIC/S recommendation on QMS requirements for Pharmaceutical Inspectorates 
[5] advises on the assessment of Internal Audit within a QMS under inspection. Therefore, 
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The quality standards of the International Standards Organisation (ISO) were also included in 
the review. The review included both the current version of the general quality standard, ISO 
9001:2015 Quality Management Systems [6] and the specific requirements for the Medical 
Device industry – ISO 13485:2016 [7]. The ISO suite of standards also has a specific standard 
for the application of internal audit – ISO 19011:2018 Guidelines for Auditing Management 
Systems [8]. This standard details expectations in relation to internal audit and is referenced 
in the PIC/s document previously mentioned and was, therefore, included in this review.  
Both the EU GMP Requirements – Eudralex Volume 4 [1] (specifically Chapters 1 and 9) as 
well as those documented in the Good Vigilance Guidance [9] were included. Although GVP 
guidances do not form part of the EU GMP requirements, they contain much more detailed 
recommendations on self-inspections and therefore were included in this review. 
 
2 Cross Reference to ISO 19011 
Table 1: Summary of Review of Regulations, Standards & Guidance 









ISO 9001 [6]/ 







Procedure in Place  X X X X X X 
Details within procedure   X X X  X 
Risk Based approach to 
planning (frequency) 
  X X X X X 
Risk factors defined   X X X X  
Auditor competency X X X X X X X 
Auditor competency 
details  
    X X X2 
Records of Findings X X X X X X X 
Use of CAPAs X X X X X X X 
Incorporated root cause 
and impact analysis 
     X  
Records review by 
Management 
X X X X X X X 
Specific reference to 
audit area management  
   X X X  
Re-audit  X   X X  
Audit programme 
evaluation 
    X X  
4





The outcome of this analysis is summarised in TABLE 1. The comparison established, that 
although there are many common requirements, there are some differences in expectations 
and also in the level of detail.  
For example, the use of a risk-based approach to the determination of frequency and duration 
of self-inspection is not mentioned in either of the regulations included in the review – 
Eudralex Volume 4 or 21 CFR 820. However, it is mentioned in the guidance and standards 
reviewed. The usefulness of the risk-based approach has, however, been mentioned in 
presentations by competent authorities [10] and may be regarded as a current expectation 
of the process. By identifying those areas within the operation that are most complex or that 
have indicated negative trends within the QMS e.g., monitoring of issues, change or 
competence – the programme can more effectively apply its resources.  This is an approach 
taken by the authorities themselves when assessing audit frequency and duration of facilities 
[11]. It is therefore included as an expected application in this work. In addition to using a risk 
based approach for determining frequency and duration, Jeroncic [12] describes the use of risk based approach 
as part of planning and conducting of self-inspection to ensure their effectiveness. 
Another interesting example of inconsistency is the requirement for auditor impartiality and 
competency. While this is a requirement described in both EudraLex Volume 4 and 21 CFR 
820.22, there are no further details outlined. ISO 19011:2018 does detail these requirements 
and this standard is cross- referenced in the PIC/s QMS requirements for Pharmaceutical 
Inspectorates. This indirect reference implies that is an expectation. The matrix of 
expectations was used to inform the developed tool. However, to assist in resolving some of 
these inconsistencies in expectations, the interview with a regulatory authority 
representative was included in the process.  
In an interview with a regulatory authority senior GMP Inspector, O’Donnell [13] highlights 
some areas within a self-inspection program that should be critically examined in order to 
increase value of their self-inspection program thereby improving effectiveness. One of the 
areas described is that the inspections are carried out in the right areas, in the right intervals, 
and by the right personnel. Such criterion have also been identified throughout the analysis 
as per TABLE 1 as well as being incorporated into the SI-PEA tool. 
5
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Further literature review focused on the measurement of effectivity of the self-inspection 
system. There were some informative contributions. Hanim Fraudziah et al [14] described 
measuring the effectiveness of self-inspection based on a review of the self-inspection 
procedures and assessing compliance with the applicable standards. However, these authors 
considered that this approach represents an audit of the compliance of the audit process and 
does not constitute a measure of its effectiveness.  
Dittenhofer [15] approached measuring effectiveness by reviewing audit outcomes. An audit 
programme was considered effective when there were no findings or when findings were 
resolved. This approach is common in the pharmaceutical industry as evidenced by a survey 
conducted as part of this research. However, the flaw with this approach is the inability to 
determine whether a lack of audit findings is due to satisfactory implementation of the QMS 
or an incompetence of the self-inspection programme with respect to identifying deficiencies. 
This research concluded that this approach alone was not an adequate assurance of effective 
application of the programme.  
To further develop this review, the work of O’Mahony [16] was studied in detail. O’Mahony 
analysed the findings of one regulatory authority – the HPRA (Health Products Regulatory 
Authority of Ireland) with respect to self-inspection deficiencies identified in inspections from 2013-
2017 (Table 2). Note this does not reflect all inspection types performed by the HPRA. 
 
Table 2: Summary of HPRA Self-Inspection Findings 2013-2017 
Of interest from this study is that compliance with the requirements, as suggested by Hanim 
Fraudziah, is a performance factor that cannot be excluded from an assessment of the 
programme, as it represents the most common deficiency. However, this may also be due to 
a lack of clarity on the details of expectations in this area. O’Mahony concluded in her work, 
that further clarity in the regulations would improve the application of the programme.  
Deficiency Type # times 
cited 
Lack of/ Inadequate Procedure 14 
Failure to apply Quality Risk Management 14 
Lack of Management Commitment 11 
Audit Resources/ Training 11 
Schedule Adherence 11 
CAPA implementation and closure 8 
6





It was further noted that failure to apply a risk-based approach to the programme was also a 
common deficiency. This assured these authors that including the requirements of related 
guidance’s and recommendations was appropriate to assure that current expectations of the 




The author of the previously referenced work, Denise O’Mahony, is a Pharmaceutical Assessor 
at the HPRA. This interviewee was chosen based on her current role, her experience working 
in a regulatory authority, and her own research work on the topic through her M.Sc. 
dissertation titled ‘GMP Chapter 9 Self Inspection Programme’ [16] and related presentations 
[17]. It is important to note, however, that the views expressed were personal reflections 
based on research and, while offering a perspective from outside industry, the views 
expressed did not represent those of the HPRA and should not be concluded as such. 
The interview was conducted through email. The questions were based on the research work 
of the interviewee and were designed to inform the proposed tool. When asked about key 
identifiers of effectiveness for a self-inspection programme the interviewee highlighted the 
importance of both overall programme structure and management commitment, while 
noting the challenge in effectively measuring the latter. This was considered when designing 
the assessment tool and an assessment of management involvement was included.  
The interviewee was also asked for her views on the potential usefulness of an assessment 
tool and if it would be of benefit in a regulatory inspection. She expressed a view that an 
appropriate tool could be used to demonstrate the effectiveness of Self Inspection within the 
PQS. She noted the importance of being able to demonstrate the effectiveness of the 
pharmaceutical quality system, a key requirement in availing of any regulatory relief. This is 
an opinion echoed by her HPRA colleague - O'Donnell [10] who has stated that, ‘A key to 
(regulatory) relief is demonstrating the effectiveness of the Pharmaceutical Quality System, as 
outlined in the ICH Q10 annex’. Consequently, the proposed tool uses a risk-based approach 
and incorporates the principles of ICH Q9: Quality Risk Management [18] and Q10. 
7
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The interviewee was also asked her opinion on whether informal tools or independent checks, 
such as walkabouts, mini audits, or checklists, might be useful to supplement the formal 
audits of a self-inspection programme. The interviewee did not have a definitive view and 
highlighted that this could depend on the process in question. To this point, the industry 
survey as described in the next section, showed 40% of respondents using a combination of 
tools as part of their self-inspection programme. These tools were considered particularly 
effective at identifying opportunities for improvement. Continuous improvement is an 
important element when demonstrating the effectiveness of the overall QMS.  
 
Industry Research – Survey 
 
To understand how self-inspection programmes are currently monitored and determined to 
be effective, a research survey was conducted using a ‘Self-Inspection Programme 
Effectiveness Questionnaire’. The survey consisted of 15 questions, designed to inform the 
development of a risk-based measurement tool.  
The form consisted of three sections; The first section was designed to establish the 
demographic of the responders, establish the industry sector in which they worked, and the 
role they had within the organisation. The second section was aimed at understanding the 
responder’s general opinion towards a self-inspection programme. The third section 
attempted to clarify the respondents own self-inspection programmes and process. 
Section 1 – REPONSE DEMOGRAPHIC 
Due to COVID-19 restrictions, Microsoft Forms was used to conduct the survey. The link was 
shared through LinkedIn and by direct email. Therefore, it is difficult to evaluate the number 
of respondents invited to contribute with the number of responses received. In total, 25 
respondents completed the survey within 30 days of release. All respondents completed 
every question, including the open free text questions.  
Most of the respondents worked within the Biopharmaceutical industry (52%), a further 28% 
within Pharmaceutical, and 8% in the Medical Device sector. Of the 25 user respondents, 15 
worked within Quality Assurance and 6 worked in Quality Control. Two of the respondents 
were heads of site and internal auditors. 
8





Section 2 – Role of Self Inspection 
When asked to rate the value of a self-inspection on a scale of 1-5 (1=low /5=high) responses 
ranged from 3 to 5, with an average score of 4.4. This indicates that the programme is 
considered a valued element in the quality management system. Respondents were asked to 
provide a free text reason for this score and the replies are summarised in Table 3. 
Table 3: Reasons why the Self Inspection Programme is valued 
 
It was noted that these reasons were provided by those that assigned a high value score to 
the programme (4-5). Three respondents assigned a lower score of 3 to the programme, 
explaining that the self-inspection programme was not applied with the same level of rigidity 
as external or regulatory audits. 
 
 
Figure 1: Survey summary responses 
It was clear from the responses that the respondents considered the Self Inspection 
programme as a valued element of the quality management system and that it was viewed 
as a key tool for assuring compliance in regulatory audit. Given that it was considered such a 
valued system, it was therefore interesting to determine how it was monitored by the 
respondents.  
No. Responses Reasoning 
8 External audit readiness / GMP compliance 
13 Continuous Improvement opportunity / way to highlight problem areas. 
9
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88% of respondents indicated that they apply a categorisation scheme to the findings of Self 
Inspection. This is consistent with both ICH Q10 and ISO 19011:2018, both of which 
recommend ranking findings to prioritise findings and aid in determining the scope of the 
CAPA (Corrective and Preventive Actions) required.  
 
To determine if these internal audits were a robust preparation for a regulatory audit, 64% 
indicated up to 25% of findings were categorised as major. This indicates that the programme 
is contributing to the prevention of findings in regulatory audit. However, it reveals little 
information about the overall effectiveness of the programme or of its role in continuous 
improvement.  
 
Section 3 – Monitoring Self Inspection 
When asked how the effectiveness of their self-inspection programme is measured (free text), 
30% indicated that it was not measured. Considering how valued the system was rated, this 
appeared to be high. Of those that did measure the system, 55% indicated that the evaluation 
was based on the number of CAPA’s raised, their timely closure, and lack of re-occurrence of 
the issue. When asked, the respondents indicated that these were also the criteria used to 





3 Management Review, a periodic evaluation of the QMS, is also a requirement of many quality standards. 
How is the Effectiveness of the Self Inspection 
Programme Measured?
Not Measured Compared to External Audit Findings Review of CAPA Closure
10






This is significant to this research as it provided evidence that, despite being a means of 
monitoring the QMS, the programme itself does not have a comprehensive measurement or 
monitoring system.   
To get full value from the survey, it was decided to add some questions relating to the 
application of Quality Risk Management (QRM). It was noted in the literature review that this 
was a concern to regulatory inspectors and, in O’ Mahony’s work, it was a significant reason 
for regulatory citations. When asked how the frequency of self-inspections is determined, 
only 68% responded with ‘based on Risk Assessment’. When surveyed for key influences in 
deciding audit scope, 20% indicated that it is solely based on previous audit history. Based on 
the responses, it can be deduced that between 20-30% of self-inspection programmes do not 
include a risk-based approach to determining audit frequency and scope.  
Responders were also asked about the level of formality applied to the self-inspection 
programme and were asked about the use of formal and informal tools. The use of less formal 
continuous improvement tools e.g., Gemba walks, personnel discussions, or interviews, 
provide potential to reduce the number of formal audits, as suggested by Duran [19]. 52% 
responded that only formal audits processes were used, while only 40% indicated that they 
used a combination of informal tools and formal audits. Further questions determined that 
of the 13 respondents who reported using formal audits only, 6 of them do, in fact, use 
additional tools as part of their self-inspection programme, but do not see them as a means 
of broadening the impact of the programme.  
 
Development of the SI-PEA Tool 
 
Using a template previously developed by Mulholland to apply a risk-based approach to 
determining the frequency, duration, and scope of self-inspection, the authors applied the 
outcomes of the above research to develop an assessment tool. It was decided to apply 10 
criteria to the assessment, including those criteria already applied within all companies 
surveyed i.e., adherence to schedule, number of findings, CAPA implementation, and lack of 
issue re-occurrence.  
11
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 Based on all the considerations previously mentioned, the authors added the criteria 
identified when analysing the requirements of the regulations, standards and guidance and 
the most common reasons for self-inspection deficiencies in regulatory audit– compliance of 
the programme and the application of QRM. Table 4 indicates the criteria used and the 
justification for the application of each effectivity measurement criteria. 
 
Figure 2: Self-Inspection Programme Effectiveness Assessment (Makarevich,2020) 
 
A ranking system was developed, ranking each criterion with a score from 0 to 5, where 0 
indicates good compliance and a low level of risk and 5 indicates potential area of 
improvement for the self-inspection programme. Makarevich developed an excel 
spreadsheet and applied a drop-down menu option to prevent values outside of this rank 
rating from being selected. The overall rank was calculated across all 10 criteria. The lower 
the score, the greater the performance with the system. The maximum risk score value is 90, 
indicating a total lack of effectiveness. A fully effective programme, requiring no 
improvement, could score the lowest risk value of Zero. 
The total score obtained when assessed across all criteria gives the user an indication of the 
overall effectiveness of the programme and indicates both the level of improvement required 
and indicates the areas where such improvements can be made. The total rank field was also 




If Total Rank Score >60, major improvements to internal audit 
programme are required ● 
If Total Rank Score >30, deficiencies in the internal audit 
programme ● 
If Total Rank Score <30, areas of improvement identified for 
audit programme effectiveness ● 
12





Table 4: Criteria inclusion justification breakdown 
# Criteria Justification for Inclusion 
1.1 Is risk assessment 
conducted for developing 
the schedule? 
 
The use of a risk-based approach to scheduling is highlighted in a number of standards and 
guidance’s reviewed:  
ISO 19011:2018 6.3.2.1 which describes using a risk-based approach to planning an audit 
The GVP Guideline ‘Risk assessment should be documented for planning of audit activity’ 
ISO13485: 2016 Section 8.2.4 states that an audit programme plan should take into 
consideration the process, the area and previous audit results. 
ICH Q9 also suggests that quality risk management can be used to define frequency and 
scope of audits 
1.2 Does it include factors 
such as scope, time, 
team. 
 
ISO 19011:2018 5.2 specifies that each audit must be based on defined objectives, scope and 
criteria. 
The requirement for audit criteria, scope and frequency being defined and recorded is also 
highlighted in ISO 13485:2016 8.2.4 and ISO 9001:2015 9.2 
2.1 Calculate % of CAPA's 
closed on time 
ISO 9001:2015 and ISO13485:2016 specify the requirement for management to ensure all 
corrective and correction actions are taken without any undue delay. 
This is also included based on the output of the industry survey. 
This criterion also aids in monitoring management commitment, as indicated by O’Mahony. 
It can also identify opportunity for improvement addressing audit findings. 
3.1 Is tracking performed? 
 
ISO 19011:2018 states that implementation of the audit programme should be monitored 
and measured. 
4.1 Are training requirements 
described in procedure? 
 
Although all guidance reviewed discuss the competency of auditor, ISO 19011:20185 
provides the additional requirement of having sector specific knowledge, completion of an 
auditor training programme and having technical experience of the management system. It 
also advises experience acquired under supervision of an experienced auditor. 
The GVCP Guideline advises that auditors should have both education in the area and 
relevant work experience 
4.2 Is there evidence of 
training in area under 
audit? (technical 
knowledge) 
ISO 19011:2018 specifies the requirement for relevant technical knowledge of the area 
under audit and, if not available, that extremal resources with the relevant knowledge 
maybe used as part of an audit team. 
5.1 Is there a management 
sign off on reports? 
 
ISO13485:2016 8.2.4 states that management responsible for the area to be audited should 
ensure the actions are taken. Area management signatures on an audit report provides 
evidence for this requirement. 
5.2   Is the data presented at 
management review? 
 
This potential failure mode was highlighted based on the number of deficiencies found by 
HPRA (O’Mahony).  
Management commitment is also required by 21 CFR 820 and the ISO standards,  
The requirement for management review is also outlined in ICH Q10 section 3.2.4 
6.1     Description of how audit 
is performed (as opposed 
to how it is documented) 
Both EU GMP Chapter 9 and 21 CFR 820 require a procedure to be in place.  
The ISO standards define the process steps that should be included in the procedure. 
6.2      Clear definitions  Clear definitions within a procedure provide a guidance to how the self-inspection 
programme operates 
Different approaches may be required for different audit types. 
6.3      Clear instruction on steps 
to be taken when 
schedule not adhered to. 
 
ISO 19011:2018 describes the need to evaluate the schedule adherence 
Any deviation from the schedule may require a review to update to the initial risk 
assessment performed and therefore should be documented 
If a risk-based approach is applied when developing the schedule, this must be considered 
when the schedule is not adhered to. 
6.4     Clear timelines for raising 
issues, report closure etc 
Documented timelines for the self-inspection programme steps will facilitate in ensuring that 
it is running smoothly and aid in schedule adherence. 
13
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7.1     Are there tools used 
supplement to self-
inspection programme, 
e.g. Gemba walks, mini 
area audits 
Continuous monitoring tools such as the use of checklists, can facilitate the implementation 
of improvements between the formal process audits. These implementations can aid in 
reducing the number of findings in formal audits both as part of the programme and 
external.  
This can demonstrate improvement within the QMS, inform the risk assessment used to 
develop the schedule, or justify reduced audit frequency within a self-inspection programme 
(depending on local regulation requirements). 
8.1 What is the % of findings 
raised as per schedule 
e.g. raising CAPA 
There should be a timeframe for when findings are actioned. The adherence to the 
scheduled timeline determines the output of the programme and informs the risk based 
approach. 
 
8.2     Are findings graded based 
on severity i.e. Minor, 
Major 
 
The requirement for grading of findings is detailed ISO 9011 and in ICH Q10. Risk ranking is 
highlighted as a potential method of audit prioritization. The grading of findings aids in 
assigning timelines for finding completion and prioritising them. The grading of findings per 
area can be evaluated from previous years and incorporated as part of a risk assessment 
when establishing the schedule for subsequent years or evaluation frequency for audit 
requirement. 
8.3      Clear ownership agreed 
at audit closure for 
findings 
The timely closure of CAPA’s is assisted if clear and appropriate ownership is assigned. This 
ties in with criteria 5.1  -  management approval of the final report. 




EU GMP Chapter 9 requires that self-inspection itself should be examined as part of the 
programme. Audit of the self-inspection programme can help identify areas of improvement 
of the process and procedures 
10.1 How many findings have 
been classified as major 
within the last year 
This criterion helps evaluate the efficiency of the programme in terms of identifying process 
improvements.  
10.2 No. of findings from 
regulatory inspection 
which have been 
previously recorded in an 
internal audit 
This criterion helps evaluate if the current programme is efficient. A low score on this 
criterion indicates that the findings raised as part of a self-inspection programme have been 
managed well and a potentially verifies the root cause of the given finding. 
 
10.3 Is there an “Lessons 
learned” meetings 
following the completion 
of a self-inspection 
schedule? 
 
As per recommendation in ISO 19011 Section 5.7 ‘reviewing and improving audit 
programme’ the lessons learned from programme review should feed in as inputs towards 
programme improvement. This section of the ISO standard also specifies areas that should 
be reviewed. In addition, ICH Q9 guide for risk management highlights audits as a planned 
event which should be risk reviewed in order to take into account new knowledge and 
experience (ICH Q9) 
14





The SI-PEA Tool 
 
15
Makarevich and Mulholland: SI-PEA




Pilot Study – Self-Inspection Programme Effectiveness Assessment (SI-PEA) Tool 
 
The assessment tool was piloted in two companies to assess its practicality and whether it 
generated information that could be helpful to the organisation in determining the 
effectiveness of the programme. The study was conducted in companies who use self-
inspection to assess the effectivity of the QMS. In each case the tool was assessed by the 
persons responsible for the programme.  
Company A acts as a supplier of laboratory equipment and reagents and as a provider of 
calibration and contract testing services to the pharmaceutical industry. The QMS at Company 
A is a hybrid of paper and electronic based documentation and is designed to meet the 
requirements of ISO 9001:2016 and ISO 17025:2017 General Requirements for the 
Competence of Testing and Calibration Laboratories [20]. Company A is audited by the Irish 
National Accreditation Board (INAB) and the British Standards Institution (BSI). This company 
was considered as a pilot site because it also tested the usefulness of the tool as a monitoring 
tool for assessing the QMS of critical suppliers.  
Company B is a contract manufacturer for both the pharmaceutical and medical device 
sectors and therefore complies with the regulations of both sectors. Company B is audited by 
the US FDA, HPRA, and SGS. Due to its activity as a contract manufacturer, is also has 
numerous critical-to-business customer audits. This company considers findings by customers 
or regulatory inspectors as a significant risk and was, therefore, also a useful pilot site.  
Prior to completing the study, the participants in both companies were given background 
details to each criterion as per Table 4. Each participant completed the tool during a virtual 
meeting. This allowed the researcher to monitor the process in addition to answering any 
queries. The results obtained from each participant were not shared with the other 
participant.  
The functionality of the tool was assessed based on the following criteria. 
1. Successful completion of all required fields and ease of use 
2. Production of a realistic and reflective effectiveness score for each company 
16





3. Usefulness in identifying areas of improvement / gaps in current programme is clearly 
identifiable to each user. 
 
Outcome of Pilot Study 
 
The tool demonstrated full functionality with respect to the established criteria. With access 
to the relevant information, the users took between 15-20 mins to complete the tool, 
confirming ease of use. While there were some questions and clarifications, the users 
expressed no difficulties. The users were able to select data from a drop-down menu under 
the ‘rank’ column. Once all ranks were selected, the total rank score was calculated 
automatically.  
The total risk rank for Company A was 25, falling in the category of <30. This determined that 
overall, the programme was satisfactory, with some opportunities for improvement. The total 
rank for Company B was 28 which is also in the green risk category as per control system rank 
score indicator. This was consistent with the maturity of the QMS in both operations.  
However, both scores indicated opportunities for improvement.  The areas of improvement 
identified were as follows; 
1. Scheduling - Neither company took a risk-based approach to determining the audit 
schedule – a key reason for regulatory findings 
 
2. Timely closure of CAPA’s – Both companies identified that CAPAs closure this was an area 
of further improvement as indicated by the SI-PEA tool  
 
 
3. Procedure – Both companies identified areas of improvement within their procedures. 
Company A did not have clear descriptions of how audit is performed. Neither company 
documented instructions on required steps if schedule is not adhered to. 
 
4. Findings – Company B identified a gap with respect to clear ownership agreement of 
audit findings. This potentially contributes to timely CAPA closure being below target. 
 
 
5. Efficiency measurement – Both companies identified that there are no ‘lessons learned’ 
reviews following the completion of a self-inspection schedule.  
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Each participant found the tool useful in identifying areas of improvement, it was considered 
easy to use with clear instructions. When requested to suggest improvements of the tool, 
both recommended incorporating a prompt, prior to giving final rank score, if a section is not 




Regulatory guidance and international standards require that Self Inspections be performed 
to monitor the implementation of the QMS and to identify opportunities for improvement. 
The most common method of establishing whether the programme is effective has been to 
monitor adherence to schedule and the output in terms of findings and the implementation 
of effective CAPA actions. While these criteria are appropriate, they do not monitor the full 
expectations of the programme.  
This research has examined these expectations comprehensively and has developed a Self-
Inspection Programme Effectiveness Assessment (SI-PEA) tool to monitor all the expected 
criteria of the programme’s objectives. The tool incorporates a risk score which can be used 
to track improvement of the programme over time. It can also identify potential areas of 
improvement within a self-inspection programme and demonstrate both effectivity and 
improvement. It is easy to populate, use and interpret. The tool created should first establish 
compliance to all regulatory expectations since without compliance a self-inspection program 
cannot be effective. The SI-PEA too can be further customised depending on a companies 
activities however this should not result in removal of the existing factors discussed in the 
tool. 
When used to report the effectiveness of the programme to Management Review, it could 
assist in establishing the effectiveness of the pharmaceutical quality system, a key 
requirement to availing of any regulatory reliefs as described in Annex 1 of ICH Q10.    
The tool has further potential to monitor both maturity and effectiveness. The SI-PEA tool is 
a preliminary model some further work to develop further criteria would develop the latter. 
In addition, further development  could also assist with monitoring the Self-Inspection 
18





effectiveness of a suppliers QMS or of a provider of outsourced activity. It also has the 
potential to be used by regulatory inspectors. 
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